Company Filing History:
4 out of 3,923 
4 out of 2,597 
Years Active: 2020-2024
Title: Gregory Beatty: Innovator in Immunotherapy
Introduction
Gregory Beatty is a prominent inventor based in Philadelphia, PA (US). He has made significant contributions to the field of immunotherapy, particularly in the development of chimeric antigen receptors (CARs). With a total of 4 patents to his name, Beatty's work focuses on innovative methods for treating diseases associated with mesothelin expression.
Latest Patents
One of Beatty's latest patents is titled "Human mesothelin chimeric antigen receptors and uses thereof." This invention provides compositions and methods for treating diseases linked to mesothelin expression. It includes a chimeric antigen receptor specific to mesothelin, along with vectors encoding the receptor and recombinant T cells that incorporate the mesothelin CAR. Additionally, the patent outlines methods for administering genetically modified T cells that express a CAR with a mesothelin binding domain.
Another significant patent is "Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy." This invention offers compositions and methods for regulating the specificity and activity of immune effector cells used in immunotherapy. It introduces a type of chimeric antigen receptor known as 'NKR-CAR,' which incorporates components of receptors naturally found on natural killer (NK) cells. The invention includes naturally occurring activating and inhibitory receptors of NK cells, such as killer cell immunoglobulin-like receptors (KIR).
Career Highlights
Gregory Beatty has worked with notable organizations, including Novartis AG and the University of Pennsylvania. His experience in these institutions has allowed him to advance his research and contribute to the field of immunotherapy significantly.
Collaborations
Throughout his career, Beatty has collaborated with esteemed colleagues, including Boris Engels and Neeraja Idamakanti. These partnerships have further enriched his research and innovation in the field.
Conclusion
Gregory Beatty is a key figure in the development of innovative therapies targeting mesothelin and immune effector cells. His patents reflect a commitment to advancing immunotherapy and improving treatment options for patients.